Genmab — September 2019
-
Mogan...Vi nævner gerne kurs, procenter men aldrig kroner og øre her i chatten.
-
-
@Sukkeralf I think someone has been reading along here today
GEN1042 Safety Trial in Subjects With Malignant Solid Tumors https://clinicaltrials.gov/ct2/show/NCT04083599?term=NCT04083599&rank=1 -
-
Fred være med det Mogan.
-
-
House Speaker Nancy Pelosi's House medicinpris udkast er ude i Washington og i medierme. Det er et meget aggressivt udkast og kan være årsagen til de store fald i aktiekurserne de seneste dag. Hele udkastet er her: https://src.bna.com/LdU
-
Gamle data fra Checkmate-017 med Opdivo (PD1) var 20% ORR i NSCLC second line http://www.newevidence.com/oncology/checkmate-017-a-phase-iii-study-of-nivolumab-versus-docetaxel-in-previously-treated-advanced-or-metastatic-squamous-cell-non-small-cell-lung-cancer/
-
Fra CheckMate-057: 19% ORR https://www.nejm.org/doi/full/10.1056/NEJMoa1507643
-
Fra KEYNOTE-024 med naive pts og Keytruda 44,8% ORR https://www.nejm.org/doi/full/10.1056/NEJMoa1606774
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind